| Dr Ray Earl Wilt Iii, DO | |
|
426 Calef Highway, Barrington, NH 03825 | |
| (603) 664-9003 | |
| (603) 664-0133 |
| Full Name | Dr Ray Earl Wilt Iii |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 426 Calef Highway, Barrington, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770757692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 15010 (New Hampshire) | Primary |
| 207Q00000X | Family Medicine | OS014529 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cornerstone Vna | Rochester, NH | Home health agency |
| Wentworth Home Care & Hospice, An Amedisys Partner | Somersworth, NH | Hospice |
| Frisbie Memorial Hospital | Rochester, NH | Hospital |
| Wentworth-douglass Hospital | Dover, NH | Hospital |
| Portsmouth Regional Hospital | Portsmouth, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appledore Medical Group Inc | 5698666154 | 89 |
News Archive
Tackling fuel poverty in the homes of people with sickle cell disease could reduce debilitating attacks and save significant money for the NHS, according to a study by Sheffield Hallam University funded by the Chesshire Lehmann Fund.
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The production of new neurons in the adult normal cortex in response to the antidepressant, fluoxetine, is reported in a study published online this week in Neuropsychopharmacology.
› Verified 1 days ago
| Entity Name | Appledore Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720077167 PECOS PAC ID: 5698666154 Enrollment ID: O20040601000165 |
News Archive
Tackling fuel poverty in the homes of people with sickle cell disease could reduce debilitating attacks and save significant money for the NHS, according to a study by Sheffield Hallam University funded by the Chesshire Lehmann Fund.
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The production of new neurons in the adult normal cortex in response to the antidepressant, fluoxetine, is reported in a study published online this week in Neuropsychopharmacology.
› Verified 1 days ago
| Entity Name | Frisbie Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942426952 PECOS PAC ID: 7012996275 Enrollment ID: O20040720000566 |
News Archive
Tackling fuel poverty in the homes of people with sickle cell disease could reduce debilitating attacks and save significant money for the NHS, according to a study by Sheffield Hallam University funded by the Chesshire Lehmann Fund.
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The production of new neurons in the adult normal cortex in response to the antidepressant, fluoxetine, is reported in a study published online this week in Neuropsychopharmacology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ray Earl Wilt Iii, DO 23 Plumer Rd Unit 23, Unit 12, Epping, NH 03042-1713 Ph: (603) 734-2567 | Dr Ray Earl Wilt Iii, DO 426 Calef Highway, Barrington, NH 03825 Ph: (603) 664-9003 |
News Archive
Tackling fuel poverty in the homes of people with sickle cell disease could reduce debilitating attacks and save significant money for the NHS, according to a study by Sheffield Hallam University funded by the Chesshire Lehmann Fund.
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The production of new neurons in the adult normal cortex in response to the antidepressant, fluoxetine, is reported in a study published online this week in Neuropsychopharmacology.
› Verified 1 days ago
Dr. Tracy Hamill, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 425 Rte 125, Barrington, NH 03825 Phone: 603-664-9003 Fax: 603-664-7493 | |
Bhavik Kiran Bhulabhai, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Century Pines Dr Ste 2, Barrington, NH 03825 Phone: 603-664-2135 Fax: 603-664-9128 | |
Joan D Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Century Pines Dr, Suite 2, Barrington, NH 03825 Phone: 603-664-2135 Fax: 603-664-9128 | |
David A Cooper, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 8 Century Pines Drive, Suite 2, Barrington, NH 03825 Phone: 603-664-2135 Fax: 603-664-9128 |